Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.76 |
| ▸ | DRD3 | P35462 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | DRD2 | P14416 | 2/20 | 0.76 |
| ▸ | HTR2B | P41595 | 2/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.76 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.76 |
| ▸ | HTR3B | O95264 | 1/20 | 0.76 |
| ▸ | MPO | P05164 | 1/20 | 0.76 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.76 |
| ▸ | DRD4 | P21917 | 1/20 | 0.76 |
| ▸ | HTR2A | P28223 | 1/20 | 0.76 |
| ▸ | HTR2C | P28335 | 1/20 | 0.76 |
| ▸ | HTR3A | P46098 | 1/20 | 0.76 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.76 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415873 | 0.86 | ADRA2A (0.74) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Metoclopramide SCHEMBL28222039 | 0.86 | HTR4 (1.00) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Metoclopramide SCHEMBL18629 | 0.86 | HTR4 (1.00) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| SCHEMBL2624889 | 0.86 | ADRA2A (0.74) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Bromopride SCHEMBL54497 | 0.86 | ADRA2A (1.00) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Metoclopramide SCHEMBL27855472 | 0.86 | HTR4 (1.00) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Bromopride SCHEMBL8385045 | 0.85 | ADRA2A (0.98) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Metoclopramide SCHEMBL678940 | 0.85 | RAB9A (1.00) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Metoclopramide SCHEMBL8160010 | 0.85 | HTR4 (0.98) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Metoclopramide SCHEMBL10385638 | 0.85 | HTR4 (0.98) | ADRA2ACYP2D6DRD3LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185499-A1 | OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS | NEKTAR THERAPEUTICS | 2018-07-05 | — | — | US | disclosed |
| US-9937266-B2 | Oligomer-containing benzamide-based compounds | NEKTAR THERAPEUTICS (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160339108-A1 | OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS | NEKTAR THERAPEUTICS | 2016-11-24 | — | — | US | disclosed |
| US-9375486-B2 | Oligomer-containing benzamide-based compounds | NEKTAR THERAPEUTICS (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150250894-A1 | Oligomer-Containing Benzamide-Based Compounds | NEKTAR THERAPEUTICS (US) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160339108-A1 | OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS | BRDT, BIRC5, BRD8 | ADRA2A 2157/4885CYP2D6 4410/4885DRD3 1489/4885 |
| US-20150250894-A1 | Oligomer-Containing Benzamide-Based Compounds | BIRC5, BRDT, TBCB | ADRA2A 1871/4885CYP2D6 4406/4885DRD3 1473/4885 |
| US-20180185499-A1 | OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS | BRDT, BIRC5, BRD8 | ADRA2A 2157/4885CYP2D6 4410/4885DRD3 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.